AbbVie
MacroGenics and AbbVie Discontinue Development of ADAM9 Antibody-Drug Conjugate (IMGC936)
MacroGenics, AbbVie, Partnered ADC, ADAM9, IMGC936, Early Data, Safety Concerns, Efficacy Issues
AbbVie pours $223M into building out its biologics capacity in Singapore
Biological Factors, expansion, AbbVie, Capacity, Investments, Manufacture, Singapore